Marc Wade Rosenbaum Sells 816 Shares of iRhythm Technologies (NASDAQ:IRTC) Stock

iRhythm Technologies (NASDAQ:IRTC) CAO Marc Wade Rosenbaum sold 816 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $128.45, for a total value of $104,815.20. Following the completion of the transaction, the chief accounting officer owned 16,706 shares in the company, valued at approximately $2,145,885.70. This represents a 4.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Marc Wade Rosenbaum also recently made the following trade(s):

• On Wednesday, February 25th, Marc Wade Rosenbaum sold 4,797 shares of iRhythm Technologies stock. The stock was sold at an average price of $135.42, for a total value of $649,609.74.
• On Tuesday, February 24th, Marc Wade Rosenbaum sold 280 shares of iRhythm Technologies stock. The shares were sold at an average price of $140.91, for a total transaction of $39,454.80.

iRhythm Technologies Stock Up 1.7%

Shares of NASDAQ IRTC opened at $127.95 on Thursday. iRhythm Technologies has a 1 year low of $92.52 and a 1 year high of $212.00. The firm’s 50-day moving average is $158.44 and its 200-day moving average is $169.85. The company has a current ratio of 4.63, a quick ratio of 4.48 and a debt-to-equity ratio of 4.25. The firm has a market capitalization of $4.14 billion, a PE ratio of -91.39 and a beta of 1.09.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings results on Thursday, February 19th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.27. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 28.15%. The business had revenue of $208.89 million during the quarter, compared to the consensus estimate of $202.61 million. During the same period in the previous year, the firm posted ($0.04) earnings per share. iRhythm Technologies’s revenue for the quarter was up 27.1% compared to the same quarter last year. Equities analysts expect that iRhythm Technologies will post -1.98 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on IRTC. JPMorgan Chase & Co. decreased their price objective on iRhythm Technologies from $240.00 to $215.00 and set an “overweight” rating for the company in a research note on Friday, February 20th. Morgan Stanley restated an “overweight” rating on shares of iRhythm Technologies in a research report on Monday, January 12th. Evercore upgraded shares of iRhythm Technologies from an “in-line” rating to an “outperform” rating and increased their price target for the company from $194.00 to $210.00 in a research report on Monday, January 5th. Canaccord Genuity Group decreased their price objective on shares of iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating for the company in a report on Friday, February 20th. Finally, Freedom Capital raised shares of iRhythm Technologies to a “strong-buy” rating in a research note on Thursday, January 15th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $211.62.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IRTC. Royal Bank of Canada increased its position in shares of iRhythm Technologies by 423.0% during the first quarter. Royal Bank of Canada now owns 7,573 shares of the company’s stock worth $793,000 after acquiring an additional 6,125 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in iRhythm Technologies by 33.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 433,780 shares of the company’s stock worth $45,408,000 after purchasing an additional 108,941 shares during the period. Strs Ohio acquired a new position in iRhythm Technologies in the 1st quarter worth $147,000. AlphaQuest LLC raised its stake in shares of iRhythm Technologies by 344.2% in the 2nd quarter. AlphaQuest LLC now owns 1,257 shares of the company’s stock valued at $194,000 after purchasing an additional 974 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in shares of iRhythm Technologies by 4.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 4,769 shares of the company’s stock valued at $734,000 after purchasing an additional 194 shares during the period.

Key iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $870.0M–$880.0M versus consensus near $817M, signaling stronger demand and faster revenue growth than expected; the company also reported a solid February quarter beat (revenue +27% YoY and EPS above estimates), supporting the outlook.
• Neutral Sentiment: Analysts are recalibrating assumptions: several firms trimmed price targets while mostly keeping Buy/Overweight ratings — that creates mixed analyst signals as models are adjusted around the new guidance and profitability timing. Analyst coverage note
• Negative Sentiment: Clustered insider selling on March 2: multiple senior executives (CAO and several EVPs) sold shares — collectively roughly 17.8k shares for ≈$2.3M at ~ $128.44 per share — a mid‑single‑digit reduction in each holder’s stake. While insiders still retain material positions, the concentrated timing of the sales is likely weighing on near‑term sentiment. Insider trades alert

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.